News

Press Releases

Hogan Lovells is sole law firm to win spot in Points of Light 2018 Civic 50 list

Washington, D.C., 19 June 2018 – Hogan Lovells has won a coveted spot in the Points of Light Civic 50, an annual list recognizing the most community-minded firms in the U.S. It is the ...

Press Releases

Hogan Lovells advises NAAFI Pension Fund Trustees on a Crown Guarantee

The Secretary of State for Defence has executed a Crown Guarantee in favour of the Trustees of the NAAFI Pension Fund (the "Trustees" and the "Fund").  Hogan Lovells advised the...

Press Releases

Hogan Lovells achieves WILEF Gold Standard recognition for sixth consecutive year

Washington, D.C., 15 June 2018 – Hogan Lovells is pleased to announce that it has been awarded the 2018 Gold Standard Certification by the Women in Law Empowerment Forum (WILEF).

Press Releases

Hogan Lovells advised Smurfit Kappa on the sale of their packaging facilities in Baden

Led by Düsseldorf partner Jens Uhlendorf Hogan Lovells has advised Ireland based Smurfit Kappa on the sale of their shares in Smurfit Kappa Baden Board GmbH, with board and packaging...

Press Releases

Hogan Lovells advises Commerzbank AG on share dividend of Vonovia SE

Led by Frankfurt based partner Michael Schlitt Hogan Lovells has advised for a second consecutive year Commerzbank AG on the payment of a share dividend and a rights issue in connection...

Press Releases

Hogan Lovells represents OptiNose in public offering

Philadelphia, 12 June 2018 – Hogan Lovells advised OptiNose, Inc., a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and...

Press Releases

New space, new face: Hogan Lovells expands in Birmingham

Global law firm Hogan Lovells has moved into a new office space in one of the most prominent office addresses in the heart of Birmingham’s premier business district, now occupying the ...

Press Releases

Hogan Lovells represents Sesen Bio in public offering

Philadelphia, 6 June 2018 – Hogan Lovells advised Sesen Bio, Inc., a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of...

Loading data